Your browser is no longer supported. Please, upgrade your browser.
OYST Oyster Point Pharma, Inc. daily Stock Chart
Oyster Point Pharma, Inc.
Index- P/E- EPS (ttm)-2.75 Insider Own1.20% Shs Outstand21.37M Perf Week-9.63%
Market Cap672.34M Forward P/E- EPS next Y-4.04 Insider Trans0.00% Shs Float7.58M Perf Month-6.89%
Income-58.50M PEG- EPS next Q-0.81 Inst Own78.90% Short Float5.21% Perf Quarter-15.72%
Sales- P/S- EPS this Y-167.20% Inst Trans2.61% Short Ratio2.74 Perf Half Y-5.02%
Book/sh5.71 P/B4.57 EPS next Y-20.60% ROA-52.70% Target Price- Perf Year-
Cash/sh4.99 P/C5.23 EPS next 5Y- ROE-160.40% 52W Range13.26 - 41.37 Perf YTD6.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.91% Beta-
Dividend %- Quick Ratio13.40 Sales past 5Y- Gross Margin- 52W Low96.83% ATR1.83
Employees30 Current Ratio13.40 Sales Q/Q- Oper. Margin- RSI (14)34.40 Volatility5.69% 6.83%
OptionableNo Debt/Eq0.00 EPS Q/Q-323.80% Profit Margin- Rel Volume0.53 Prev Close26.10
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume144.03K Price26.10
Recom2.00 SMA20-11.13% SMA50-12.41% SMA200-6.07% Volume0 Change0.00%
Nov-25-19Initiated Piper Jaffray Overweight $35
Nov-25-19Initiated JP Morgan Overweight $26
Nov-25-19Initiated Cowen Outperform $40
Jun-01-20 11:39AM  
May-28-20 09:07AM  
May-24-20 12:25PM  
May-19-20 06:08PM  
May-15-20 02:02AM  
May-12-20 04:20PM  
May-11-20 10:31PM  
May-04-20 04:05PM  
Mar-30-20 07:30AM  
Feb-27-20 04:01PM  
Feb-24-20 08:00AM  
Jan-12-20 08:00PM  
Dec-24-19 07:24AM  
Dec-23-19 09:00AM  
Dec-17-19 08:00AM  
Dec-03-19 03:29PM  
Nov-25-19 08:00AM  
Nov-22-19 05:12PM  
Nov-05-19 09:10AM  
Oct-28-19 08:20AM  
Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.